Moderna Chief Commercial Officer steps down, President to look over pipeline strategy
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
He has over two decades of leadership experience as an innovative strategic planner in finance diligence
Chief Imam of All India Imam Organization, Dr. Imam Umer Ahmed Ilyas, evinces keen interest in the eradication of Thalassemia & Sickle Cell Disease
He has published more than 100 research papers in several prestigious national and international journals
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
Subscribe To Our Newsletter & Stay Updated